V
Viking Therapeutics, Inc. (VKTX)
NCM – Real vaqt narxi. Valyuta: USD
31.32
-0.40 (-1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
31.20
-0.12 (-0.38%)
Bozor oldidan: May 13, 2026, 8:46 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
31.32
-0.40 (-1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
31.20
-0.12 (-0.38%)
Bozor oldidan: May 13, 2026, 8:46 AM EDT
Viking Therapeutics, Inc., klinik davr biotsenotik kompaniyasi, metabolik va endokrin kasalliklar uchun yangi davolash usullarini ishlab chiqishga qaratilgan. Uning yetakchi dorisi nomzodi VK2809 hisoblanadi, bu og'iz orqali qabul qilinadigan to'qima va retseptor ost-tipli tanlab ta'sir qiluvchi qalqonsimon bez gormoni retseptorining beta (TRß) agonisti, u biopsiya bilan tasdiqlangan alkogolsiz steatohepatit va NAFLD bemorlarini davolash uchun IIb bosqich klinik sinovlarida. Kompaniya VK5211-ni ishlab chiqmoqda, bu og'iz orqali qabul qilinadigan steroid bo'lmagan tanlab ta'sir qiluvchi androgen retseptorlari modulyatori bo'lib, u majburiy bo'lmagan son suyagi sinishi operatsiyasidan tuzalayotgan bemorlarni davolash uchun II bosqich klinik sinovlarida; VK0612, metabolik kasalliklar va kamqonlik uchun II bosqich klinik sinovlarida; VK2735, glyukagon-o'xshash peptid 1 ning yangi qo'sh agonisti, I bosqich SAD/MAD klinik sinovida; va VK0214, og'iz orqali qabul qilinadigan to'qima va retseptor ost-tipli tanlab ta'sir qiluvchi TRß agonisti bo'lib, u X-bog'langan adrenoleykodistrofiyani davolash uchun. Kompaniya 2012 yilda tashkil etilgan va San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Brian Lian Ph.D. | President, CEO & Director |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer |
| Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gregory S. Zante CPA | Chief Financial Officer |
| Mr. Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales |
| Mr. Michael Morneau | Vice President of Finance & Administration |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
| Ms. Katherine Mercier | Vice President of Quality and Compliance |
| Ms. Marianne Mancini | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 10-Q | vktx-20260331.htm |
| 2026-04-29 | 8-K | vktx-20260429.htm |
| 2026-04-01 | DEFA14A | vktx-2026-04-01-defa14a_.htm |
| 2026-02-11 | 8-K | vktx-20260211.htm |
| 2025-10-23 | 10-Q | vktx-20250930.htm |
| 2025-10-22 | 8-K | vktx-20251022.htm |
| 2025-08-19 | 8-K | vktx-20250819.htm |
| 2025-07-23 | 8-K | vktx-20250723.htm |
| 2025-05-27 | 8-K | vktx-20250520.htm |
| 2025-04-24 | 10-Q | vktx-20250331.htm |